Screening for prostate cancer: Updated experience from the Tyrol study

被引：12

作者：

Horninger W. ^{[1
]}

Berger A. ^{[1
]}

Pelzer A. ^{[1
]}

Klocker H. ^{[1
]}

Oberaigner W. ^{[1
]}

Schönitzer D. ^{[1
]}

Severi G. ^{[1
]}

Robertson C. ^{[1
]}

Boyle P. ^{[1
]}

Bartsch G. ^{[1
]}

机构：

[1] Department of Urology, University of Innsbruck, Anichstrasse 35, Innsbruck

来源：

Current Urology Reports | 2004年 / 5卷 / 3期

关键词：

Prostate Cancer; Prostate Cancer Mortality; Prostate Cancer Screening; Radical Prostatectomy; Tyrol;

D O I：

10.1007/s11934-004-0040-8

中图分类号：

学科分类号：

摘要：

The aim of the Tyrol study was to monitor the impact of screening in a natural experiment by comparing prostate cancer mortality in Tyrol, where prostate-specific antigen (PSA) testing was introduced at no charge, with the rest of Austria, where it was not strictly organized and not free of charge. In 1993, PSA testing was made freely available to men between the ages of 45 and 75 years in the Federal State of Tyrol, Austria. At least 70% of all of the men in this age range have been tested at least once during the first 10 years of the study. Initially, only total PSA was measured, but free PSA measurement was added in 1995. Since 2001, complexed PSA also has been measured. Digital rectal examination was not part of the screening examination. Significant migration to lower clinical and pathological stages has been observed since the introduction of this screening program. These findings are consistent with the hypothesis that the policy of making PSA testing freely available, and the wide acceptance by men in the population, is associated with a reduction in prostate cancer mortality in an area in which urology services and radiotherapy are available freely to all patients. It is our opinion that most of this decline is likely a result of aggressive downstaging and successful treatment and that any contribution from detecting and treating early cancers will become apparent in the years to come. © 2004, Current Science Inc.

引用

页码：220 / 225

页数：5

共 30 条

[1]

Stanford J.L., Stephenson R.A., Coyle M., Et al., Prostate Cancer Trends 1973–1995, SEER Program, pp. 7-15, (1999)

[2]

Jones G.W., Mettlin C., Murphy G.P., Et al., Patterns of care for carcinoma of the prostate gland: results of a national survey of 1984 and 1990, J Am Coll Surg, 180, pp. 545-554, (1995)

[3]

Catalona W.J., Richie J.P., Ahmann F.R., Et al., Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6630 men, J Urol, 151, pp. 1283-1290, (1994)

[4]

Ohori M., Wheeler T.M., Dunn J.K., Et al., The pathological features and prognosis of prostate cancer detectable with current diagnostic tests, J Urol, 152, pp. 1714-1720, (1994)

[5]

Smith D.S., Catalona W.J., The nature of prostate cancer detected through prostate specific antigen based screening, J Urol, 152, pp. 1732-1736, (1994)

[6]

Slawin K.M., Ohori M., Dillioglugil O., Et al., Screening for prostate cancer: an analysis of the early experience, CA Cancer J Clin, 45, pp. 134-147, (1995)

[7]

Reissigl A., Pointner J., Horninger W., Et al., Comparison of different PSA cut points for early detection of prostate cancer: results of a large screening study, Urology, 46, pp. 662-665, (1995)

[8]

Reissigl A., Pointner J., Horninger W., Et al., PSA based screening for prostate cancer in asymptomatic younger males: pilot study in blood donors, Prostate, 30, pp. 20-25, (1997)

[9]

Reissigl A., Ennemoser O., Klocker H., Et al., Frequency and clinical significance of transition zone cancer in prostate cancer screening, Prostate, 30, pp. 130-135, (1997)

[10]

Reissigl A., Klocker H., Horninger W., Et al., Usefulness of the ratio free/total PSA in addition to total PSA levels in prostate cancer screening, Urology, 48, pp. 62-66, (1996)

← 1 2 3 →